THE INDUSTRY’S DEFINITIVE MEETING TO ADVANCE THE DEVELOPMENT OF CLINICALLY TRANSFORMATIVE NEUROPSYCHIATRIC DRUGS
With the huge unmet clinical need in neuropsychiatry and despite multiple approved pharmaceuticals available, the development of the next generation of neuropsychiatric drugs is essential.
The abundance of excitement and scientific progress in the field – especially with the recent approval of esketamine – will be captured at the Neuropsychiatric Drug Development summit, in Boston on July 23 – 25, 2019.
Built with thought-leaders at Sage Therapeutics, Johnson & Johnson and Lundbeck, the 2nd Annual NPD summit will unravel the complexities of developing truly clinically transformative neuropsychiatric drugs.
Dedicated to overcoming challenges in neuropsychiatric drug development, this comprehensive discussion and networking forum will cover:
- Reviewing the current clinical landscape to share learned lessons, predict potential success and identify future opportunities
- Determine what we can expect from neuropsychiatric preclinical models to better predict clinical efficacy
- Utilize what we know from the clinical to improve our use of translational strategies
- Discuss the potential for digital therapeutics to transform the success of efficacious pharmaceuticals
- Review symptomatic focused drug development to identify the benefits and impact future regulation
- Evaluate the potential for different neuropsychiatric targets by improving our understanding of neuropsychiatric biology
- Improving our understanding of the role of genetics in neuropsychiatry and debating the future of precision medicine for neuropsychiatric disorders
Join your peers at NPD to be part of the cross-industry discussion on latest developments, insights and science to elevate clinically effective neuropsychiatric therapeutic pipelines
To learn more about this event, visit https://ter.li/belugv